Matinas BioPharma Slumps After Amarin Case Verdict
Matinas BioPharma (MTNB) stock slumped after a US District Court decided to invalidate Amarin Corporation's (AMRN) Vascepa. While the verdict is ostensibly in favor of generic drugs, Matinas stock reacted negatively to the news. However, the company tried to assuage the damage by stating that such increased competition from generic drugs is not likely to have significant negative impact on the market potential of its drug candidate MAT9001.
While Amarin announced that it intends to file an appeal and may also seek an injunction to prevent